ACADIA Pharmaceuticals Inc. (ACAD)

25.85 -0.05 (-0.19%) At close: 4:00PM EDT

ACADIA Pharmaceuticals Inc.

12830 El Camino Real
Suite 400
San Diego, CA 92130
United States
858 558 2871
http://www.acadia-pharm.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 640

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Stephen R. Davis	CEO & Director	1.23M	5.28M	1961
Dr. Srdjan R. Stankovic	Pres	1.12M	7.82M	1957
Ms. Elena H. Ridloff C.F.A., CFA	Exec. VP & CFO	646.54k	256.2k	1980
Mr. Austin D. Kim	Exec. VP, Gen. Counsel & Sec.	626.76k	240.8k	1964
Mr. James K. Kihara	VP, Corp. Controller & Principal Accounting Officer	N/A	N/A	1980
Mr. Bob Mischler	Sr. VP of Strategy & Technology Operations	N/A	N/A	N/A
Mr. Mark C. Johnson	VP of Investor Relations	N/A	N/A	N/A
Ms. Stephanie Fagan	Sr. VP of Corp. Affairs & Chief Communications Officer	N/A	N/A	N/A
Ms. Charmaine Lykins	Sr. VP of Global Product Planning & Chief Marketing Officer	N/A	N/A	N/A
Dr. Mary Ellen Turner	Sr. VP of Pharmacovigilance & Corp. Safety Officer	N/A	N/A	N/A

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Corporate Governance

ACADIA Pharmaceuticals Inc.’s ISS Governance QualityScore as of June 1, 2021 is 6. The pillar scores are Audit: 6; Board: 4; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.